For nearly a decade, scientists and entrepreneurs in the cannabis space have been developing technologies that address niche issues that are specific to the industry. As legal cannabis has become more sophisticated, a number of companies are beginning to recognize the universal applications of their technologies. This year, in the midst of a global pandemic that pushed mainstream testing and medical companies to their limits, PathogenDx adapted its microarray testing platform, originally developed to detect cannabis-specific microbes, to test for COVID-19. In this episode, CEO and co-founder Milan Patel discusses the potential universal applications of cannabis science, how PathogenDx is using its two NIH grants to advance COVID-19 diagnostic technology, and what comprehensive cannabis safety and testing standards should look like.